0001140361-15-023698.txt : 20150609 0001140361-15-023698.hdr.sgml : 20150609 20150609172632 ACCESSION NUMBER: 0001140361-15-023698 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150605 FILED AS OF DATE: 20150609 DATE AS OF CHANGE: 20150609 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO BIOSCIENCES INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 501 CANAL BLVD STREET 2: POINT RICHMOND TECH CNTR. CITY: RICHMOND STATE: CA ZIP: 94804 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 501 CANAL BLVD STREET 2: POINT RICHMOND TECH CNTR. CITY: RICHMOND STATE: CA ZIP: 94804 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ANDO DALE G CENTRAL INDEX KEY: 0001202278 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 15921744 MAIL ADDRESS: STREET 1: C/O CELL GENESYS INC STREET 2: 500 FORBES BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc1.xml FORM 4 X0306 4 2015-06-05 0 0001001233 SANGAMO BIOSCIENCES INC SGMO 0001202278 ANDO DALE G C/O SANGAMO BIOSCIENCES INC. POINT RICHMOND TECH CNTR, 501 CANAL BLVD RICHMOND CA 94804 0 1 0 0 VP, Therapeutic Dev. & CMO Common Stock 2015-06-05 4 M 0 15000 3.45 A 111763 D Common Stock 2015-06-05 4 S 0 15000 12.2929 D 96763 D Employee Stock Option (Right to Buy) 3.45 2015-06-05 4 M 0 15000 0 A 2018-12-09 Common Stock 15000 50798 D The sales reported in this Form 4 were effected pursuant to the Rule 10b5-1 trading plan adopted by the Reporting Person on June 23, 2014. Includes 11,666, 15,333 and 25,000 shares subject to RSUs granted on December 6, 2012, December 12, 2013 and December 11, 2014 respectively, which will be issued as such units vest in accordance with their terms. Includes 1,387 shares acquired by the Reporting Person on April 30, 2015 under the Issuer's Employee Stock Purchase Plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.14 to $12.46, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. All shares underlying this option are vested and immediately exercisable. /s/ Florence Tam, attorney-in-fact 2015-06-09